As of June 9, 2025, Jiangsu Bioperfectus Technologies Co Ltd (688399.SS) reports a Gross Margin of 57.77%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Jiangsu Bioperfectus Technologies Co Ltd's Gross Margin
Over recent years, Jiangsu Bioperfectus Technologies Co Ltd's Gross Margin has shown a moderate pattern. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 57.77% |
| 2023-12-31 | 37.02% |
| 2022-12-31 | 57.00% |
| 2021-12-31 | 69.00% |
| 2020-12-31 | 77.54% |
This gradual decrease highlights how Jiangsu Bioperfectus Technologies Co Ltd manages its operational efficiency and pricing power over time.
Comparing Jiangsu Bioperfectus Technologies Co Ltd's Gross Margin to Peers
To better understand Jiangsu Bioperfectus Technologies Co Ltd's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Jiangsu Bioperfectus Technologies Co Ltd (688399.SS) | 57.77% |
| Sansure Biotech Inc (688289.SS) | 81.00% |
| Kangji Medical Holdings Ltd (9997.HK) | 79.08% |
| Nanosonics Ltd (NAN.AX) | 77.90% |
| Autek China Inc (300595.SZ) | 73.24% |
| Shanghai MicroPort Endovascular MedTech Group Co Ltd (688016.SS) | 72.62% |
Compared to its competitors, Jiangsu Bioperfectus Technologies Co Ltd's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.